

Getting Your Patients Started on Lumvoa

A guide to the ViridianCares support program

ViridianCares is a support program to help your patients start and stay on treatment. This guide provides:



ViridianCares program overview



Financial assistance options



ViridianCares enrollment details



Lumvoa dosing information



Insurance coverage support



Patient preparation guidance

ViridianCares is a support program to help your patients start and stay on treatment

ViridianCares offers a range of services and programs that can help with access, affordability, and treatment support:



Dedicated Patient Access Liaisons (PALs)



Flexible ViridianCares enrollment (online/fax)



Support for insurance approval, including benefits verification, prior authorization, and reimbursement



Financial assistance programs for eligible patients



Post-infusion support materials for patients




Patient education and treatment support, including a welcome kit with infusion reminders

For more information on
ViridianCares, please visit
[ViridianCares.com](https://www.ViridianCares.com)
or call 1-866-VCARES1
Monday-Friday, 8 am to 8 pm ET

Patient Access Liaisons

Once your patient is enrolled in ViridianCares, they will be contacted by a Patient Access Liaison (PAL).

- A PAL is available to provide personalized, one-on-one support for your patients
- PALs can help navigate a wide array of issues, such as patient onboarding, insurance approvals, prior authorizations, and treatment logistics—all with the aim of helping your patients start and stay on therapy



For more information on
ViridianCares, please visit
ViridianCares.com
or call 1-866-VCARES1
Monday-Friday, 8 am to 8 pm ET

Your first step: Enrolling your patient in ViridianCares

A completed Patient Enrollment Form initiates ViridianCares support and serves as the prescription for Lumvoa. To help your patients enroll, visit www.lumvoahcp.com/content/lumvoa-patient-enrollment-form.pdf to download the enrollment form.

It is crucial to complete all required fields and ensure your patient signs and dates the Patient Authorization to Use/Disclose Health Information.

Before submitting the form, please ensure:

- The Patient Information, Prescriber Information, and Prescription sections have been completed
- The Insurance Information section has been completed OR copies of the front and back of patient's insurance card(s) have been included
- The appropriate diagnosis code has been indicated
- The Prescriber Certification has been signed
- The patient has read and signed the Patient Authorization to Use/Disclose Health Information
- The preferred infusion facility has been included. If you don't have an identified infusion facility, ViridianCares can help

All 4 pages are required for a complete submission.



Support services are available for eligible patients following submission of a completed ViridianCares Patient Enrollment Form. You may enroll patients in ViridianCares at any stage of the treatment journey by completing, signing, and submitting the ViridianCares Patient Enrollment Form.

For more information on
ViridianCares, please visit
ViridianCares.com

or call 1-866-VCARES1
Monday-Friday, 8 am to 8 pm ET

Your first step: Enrolling your patient in ViridianCares (cont'd)

Once the enrollment form is completed:



Fax all 4 pages of the
ViridianCares enrollment form
to **1-833-726-5151**

or



Complete the EZ enroll
enrollment form online at
<https://www.viridian.hcp-portal.caremetx.com/ez-enroll>

Support you and your patients can expect once enrollment is complete:



The patient, healthcare provider, and/or site of care will
receive a welcome call from the PAL to confirm the
patient's information and review next steps



Your patient will receive a welcome kit, containing
resources that will help educate patients and prepare
them for their Lumvoa infusions



The dedicated PAL will provide updates to your
patient and office about their insurance approval
process to help prepare them for their infusions

For more information on
ViridianCares, please visit
[ViridianCares.com](https://www.viridiancares.com)
or call 1-866-VCARES1
Monday-Friday, 8 am to 8 pm ET

ViridianCares is a resource for insurance coverage support

ViridianCares will conduct a benefits verification, identify insurance requirements, and explain prior authorization processes to support timely treatment management.

Benefits investigation

ViridianCares will conduct a benefits verification to obtain coverage information about your patient's insurance benefits, including prior authorization or precertification requirements, site of care requirements, Co-Pay Program eligibility, and network considerations to support Lumvoa access. ViridianCares will also assess patients for potential financial assistance programs if they are facing financial hardship, uninsured, and/or underinsured.

Prior authorization (PA)

ViridianCares provides tools and education to support PA questions. Your office must ensure the PA is accurate and complete before you submit it to the health plan. Complete, consistent, patient-specific clinical documentation that is aligned to health plan criteria language helps support medical necessity and reduce denials for Lumvoa.

If your patient is treated at an alternative site of care or infusion center, the site of care will coordinate with the prescriber to collect required clinical documentation for your prior authorization submission.

ViridianCares offers:



PA support, including education on payer-specific requirements, identification of relevant forms, and follow-up to confirm submission status and coverage determinations



Appeals support, including education on payer appeal processes and follow-up to confirm submission status and outcomes, when applicable

For more information on
ViridianCares, please visit
[ViridianCares.com](https://www.ViridianCares.com)

or call 1-866-VCARES1
Monday-Friday, 8 am to 8 pm ET

Support you and your patients can expect once the PA is submitted

After your office submits the PA:



The PAL will confirm with you that the PA has been submitted and monitor the PA status until a coverage determination is reached



If the PA is approved, the PAL will follow up with you to confirm receipt of PA approval and discuss next steps



If the PA is denied, the PAL will follow up with you and your patient to discuss the requirements to pursue an appeal and will provide education on the eligibility requirements for the Patient Assistance Program should coverage for Lumvoa be denied



Download the Letter of Medical Necessity, Letter of Appeal, and PA checklist at www.lumvoahcp.com/resources

For more information on
ViridianCares, please visit
ViridianCares.com

or call 1-866-VCARES1
Monday-Friday, 8 am to 8 pm ET

Co-Pay Program

Eligible, commercially insured patients may pay as little as \$0* in out-of-pocket costs for medication and infusion costs through the ViridianCares Co-Pay Program

Eligible, commercially insured patients

may pay as little as \$0

for medication and infusion expenses

If eligible, patients may save on medication and infusion costs if they:

- ☒ Are enrolled in ViridianCares and meet all eligibility requirements*
- ☒ Have commercial insurance (and are not enrolled in any federal or state-funded healthcare program)
- ☒ Are not receiving free drug from Viridian

*Patients must be enrolled in ViridianCares and meet all eligibility requirements. See full terms and conditions at www.lumvoahcp.com/content/lumvoa-copay-terms-and-conditions.pdf.

For more information on
ViridianCares, please visit
ViridianCares.com

or call 1-866-VCARES1
Monday-Friday, 8 am to 8 pm ET

Please see Important Safety Information on page 12
and accompanying Full Prescribing Information.

Patient Assistance Program



For eligible uninsured or underinsured patients:

If your patients experience a change in coverage or have affordability concerns, ViridianCares will work closely with them to explore available financial assistance options



A completed **Patient Assistance Program enrollment form** is required for ViridianCares to determine eligibility. For more information on Patient Assistance Program enrollment, please call your PAL




For more information on
ViridianCares, please visit
[ViridianCares.com](https://www.ViridianCares.com)

or call 1-866-VCARES1
Monday-Friday, 8 am to 8 pm ET

Lumvoa is an infusion therapy for patients with Thyroid Eye Disease

Lumvoa has a 12-week treatment course with only 5 infusions.

The recommended dose of Lumvoa is an intravenous (IV) infusion of 10 mg/kg every 3 weeks for 5 infusions.



**Single IV infusion once
every 3 weeks for 12 weeks**



Initial infusion



45 minutes

Subsequent infusions



30 minutes
if well tolerated




Download the Lumvoa Infusion Brochure for complete administration details at www.lumvoahcp.com/preparation-administration

For more information on
ViridianCares, please visit
ViridianCares.com

or call 1-866-VCARES1
Monday-Friday, 8 am to 8 pm ET

Guiding patients throughout their treatment journey



Resources are available to support your patient throughout the treatment journey



Access resources at www.lumvoahcp.com/resources

*PALs are only accessible to patients enrolled in ViridianCares.

Please see Important Safety Information on page 12 and accompanying Full Prescribing Information.

For more information on ViridianCares, please visit ViridianCares.com or call 1-866-VCARES1 Monday-Friday, 8 am to 8 pm ET

INDICATION and IMPORTANT SAFETY INFORMATION

Indication: Lumvoa is indicated for the treatment of Thyroid Eye Disease regardless of Thyroid Eye Disease activity or duration

Important Safety Information

Infusion Reactions: Lumvoa may cause infusion reactions. Infusion reactions have been reported in approximately 9% of patients treated with Lumvoa. Signs and symptoms of infusion-related reactions include transient increases in blood pressure, fever, chills, headache, and fatigue. Infusion reactions may occur during or soon after an infusion. Reported infusion reactions are usually mild or moderate in severity and can usually be successfully managed with corticosteroids, antihistamines, and antipyretics. In patients who experience an infusion reaction, consideration should be given to standard premedication and/or administering infusions at a slower infusion rate.

Inflammatory Bowel Disease: Lumvoa may cause an exacerbation of inflammatory bowel disease (IBD). IBD has been reported in some patients receiving insulin-like growth factor-1 receptor inhibitors without a prior diagnosis of IBD. Monitor patients for signs and symptoms of IBD, including patients without a history of IBD. If IBD is suspected, discontinue use of Lumvoa.

Hyperglycemia: Hyperglycemia or increased blood glucose may occur in patients treated with Lumvoa. In clinical trials, 12% of patients, of whom one half had preexisting diabetes or impaired glucose tolerance, experienced hyperglycemia. Hyperglycemic events should be controlled with medications for glycemic control, if necessary. Assess patients for elevated blood glucose and symptoms of hyperglycemia prior to infusion and continue to monitor while on treatment with Lumvoa. Ensure patients with hyperglycemia or preexisting diabetes are under appropriate glycemic control before and while receiving Lumvoa. Continued monitoring after treatment is recommended for patients who experience hyperglycemia while on Lumvoa.

Hearing Impairment Including Hearing Loss: Lumvoa may cause severe hearing impairment including hearing loss, which in some cases may be permanent. Assess patients' hearing before, during, and after treatment with Lumvoa and consider the benefit-risk of treatment with patients.

Most Common Adverse Events: Most common adverse reactions (incidence of 5% or more) are muscle spasms, headache, hearing impairment, hyperglycemia, fatigue, diarrhea, ear discomfort, infusion-related reaction, nausea, nasopharyngitis, blood creatine phosphokinase increased, dry skin, and hypertension.

Females of Reproductive Potential: Appropriate forms of contraception should be implemented prior to initiation, during treatment, and for 6 months following the last dose of Lumvoa.

Lumvoa (500 mg) is an injection for infusion.

Please see accompanying Full [Prescribing Information](#).

Reference: Lumvoa™ (veligrotug-vvze) prescribing information. Viridian Therapeutics, Inc. 2026.

© 2026 Viridian Therapeutics, Inc. All Rights Reserved.
Lumvoa™ (veligrotug-vvze), Viridian Therapeutics®, ViridianCares™,
and related trademarks are owned by Viridian Therapeutics, Inc.
US-VG-0217 06/26

